The Supreme Court on Monday restored broad access to the abortion pill mifepristone, blocking a lower-court ruling that had threatened to upend one of the main ways abortions are provided across the nation, as legal challenges continue over drug safety standards and federal regulatory authority.
The order signed by Justice Samuel Alito temporarily allows women seeking abortions to obtain the pill at pharmacies or through the mail, without an in-person visit to a doctor. Those practices had been permitted for several years until a federal appeals court imposed new restrictions last week. The latest order will remain in effect for another week while both sides respond and the high court considers the issue more fully.
State Challenge to Federal Authority
Louisiana sued to roll back the Food and Drug Administration's rules on how mifepristone can be prescribed, asserting that the policy undermines the ban there. The case also questioned the safety of the drug, which was approved 25 years ago and has repeatedly been deemed safe and effective by FDA scientists.
Louisiana Attorney General Liz Murrill, who filed the lawsuit against the FDA along with a woman who says her boyfriend coerced her into taking abortion pills to end a pregnancy, criticized drug companies for their role in the case. She said, "Big abortion pharma claims they need an emergency stay because they will lose massive amounts of money if they can't kill more babies quickly and efficiently by mail without medical oversight." She added, "The administrative stay is temporary, and I am confident life and the law will win in the end."
Market Response and Medical Alternatives
The majority of abortions in the U.S. are obtained through medications, and some Democratic-led states have laws that seek to give legal protection to those who prescribe the drugs via telehealth to patients in states with bans. The lawsuit is the furthest along of several efforts by abortion opponents to curtail access to mifepristone.
Mifepristone is usually taken with misoprostol for abortions, and according to the FDA label on mifepristone, the combination completes medical abortion 97.4% of the time. Misoprostol can also be used alone for terminating pregnancies, with some studies putting its effectiveness at around 80% or higher. In countries where mifepristone is banned or unavailable, misoprostol is frequently used alone.
Unlike mifepristone, misoprostol has never been formally approved by the FDA for abortion. The drug is most commonly used to treat stomach ulcers, but it has been adapted by doctors for use in medication abortions. Several groups that prescribe abortion pills by telehealth made the switch over the weekend to misoprostol only, a regimen that can cause longer-lasting side effects.
Provider Reactions and Broader Policy Context
Dr. Angel Foster, founder of The Massachusetts Abortion Access Project, said her organization was prepared to send misoprostol only on Monday afternoon but was able to switch back to the two-drug combination. She said, "Regardless of what happens with this regulatory issue, we and other groups will continue to provide high-quality abortion care to patients in all 50 states."
Julie Burkhart, the founder of Wellspring Health Access, a Wyoming abortion clinic that provides roughly 100 abortions a year through pills prescribed by telehealth, said, "We have a little bit more time to navigate this new landscape with the stay." Elizabeth Ling, associate director of legal services at If/When/How, said, "The outcome is not going to make it a crime for people to access care."
Carol Tobias, president of National Right to Life, said Monday's ruling "is a temporary procedural step that leaves unresolved the very real concerns about the safety of these drugs and the decision under the Biden administration's FDA to recklessly remove longstanding safeguards."
Politico also reported that the GOP health care vision would encourage Obamacare enrollees to shift into high-deductible insurance plans and that President Donald Trump and GOP senators want to shift remaining Obamacare subsidies into tax-advantaged health savings accounts. The newsletter said the plan would cut off telemedicine prescriptions of mifepristone for non-abortion purposes, such as easing miscarriages.
Why This Matters:
The Supreme Court's temporary order highlights ongoing tensions between federal regulatory authority and state sovereignty over health policy. Louisiana's challenge raises fundamental questions about FDA drug approval standards and whether federal agencies can override state laws designed to protect life. The case involves concerns about patient safety when drugs are prescribed without in-person medical oversight, particularly for procedures with potential complications. The broader GOP health care vision reported by Politico would restrict telemedicine prescriptions even for non-abortion medical purposes, reflecting concerns about appropriate medical supervision. The legal battle will determine whether states can challenge federal drug regulations they believe undermine their own public health and safety laws, with implications for federalism and regulatory authority.